Literature DB >> 19188135

Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?

J Ayllon, V Launay-Vacher, J Medioni, C Cros, J P Spano, S Oudard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19188135     DOI： 10.1093/annonc/mdn788

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  15 in total

Review 1.  Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases?

Authors:  Daniel Keizman; Maya Ish-Shalom; Natalie Maimon; Maya Gottfried
Journal:  World J Urol       Date:  2013-03-31       Impact factor: 4.226

Review 2.  Updates on osteonecrosis of the jaw.

Authors:  Junro Yamashita; Laurie K McCauley; Catherine Van Poznak
Journal:  Curr Opin Support Palliat Care       Date:  2010-09       Impact factor: 2.302

3.  Osteonecrosis of the jaw related to sunitinib.

Authors:  Felix P Koch; Christian Walter; Torsten Hansen; Elke Jäger; Wilfried Wagner
Journal:  Oral Maxillofac Surg       Date:  2011-03

4.  Osteonecrosis of the Jaw in the Absence of Antiresorptive or Antiangiogenic Exposure: A Series of 6 Cases.

Authors:  Tara L Aghaloo; Sotirios Tetradis
Journal:  J Oral Maxillofac Surg       Date:  2016-07-30       Impact factor: 1.895

Review 5.  Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review.

Authors:  Susan E Pories; Gerburg M Wulf
Journal:  Breast Cancer (Dove Med Press)       Date:  2010-06-21

6.  Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy.

Authors:  Tatjana I Jung; Falk Hoffmann; Gerd Glaeske; Dieter Felsenberg
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-22       Impact factor: 4.553

Review 7.  New cancer therapies and jaw necrosis.

Authors:  V Patel; M Kelleher; C Sproat; J Kwok; M McGurk
Journal:  Br Dent J       Date:  2015-09-11       Impact factor: 1.626

8.  Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors.

Authors:  T van Cann; T Loyson; A Verbiest; P M Clement; O Bechter; L Willems; I Spriet; R Coropciuc; C Politis; R O Vandeweyer; J Schoenaers; P R Debruyne; H Dumez; P Berteloot; P Neven; K Nackaerts; F J S H Woei-A-Jin; K Punie; H Wildiers; B Beuselinck
Journal:  Support Care Cancer       Date:  2017-09-30       Impact factor: 3.603

9.  Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.

Authors:  B Beuselinck; P Wolter; A Karadimou; R Elaidi; H Dumez; A Rogiers; T Van Cann; L Willems; J-J Body; J Berkers; H Van Poppel; E Lerut; P Debruyne; R Paridaens; P Schöffski
Journal:  Br J Cancer       Date:  2012-11-06       Impact factor: 7.640

10.  Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma.

Authors:  M Gilabert; M Provansal; M Cappiello; Y Walz; N Salem; C Tarpin; S Brunelle; J Thomassin; G Gravis
Journal:  Br J Cancer       Date:  2013-09-17       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.